Kathryn DiMarco
Comptroller/Controller/Auditor chez ORGANON & CO.
Fortune : 378 820 $ au 31/03/2024
Profil
Kathryn DiMarco is currently the Senior Vice President-Finance & Controller at Organon & Co. Prior to this, she worked as the Controller at Allergan Ltd.
(Ireland) from 2015 to 2020 and as the International Controller at Merck Sharp & Dohme Corp.
from 2014 to 2015.
She obtained her undergraduate degree from Lehigh University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ORGANON & CO.
0,01% | 31/03/2024 | 20 150 ( 0,01% ) | 378 820 $ | 31/03/2024 |
Postes actifs de Kathryn DiMarco
| Sociétés | Poste | Début |
|---|---|---|
| ORGANON & CO. | Comptroller/Controller/Auditor | 02/06/2021 |
Anciens postes connus de Kathryn DiMarco
| Sociétés | Poste | Fin |
|---|---|---|
| ALLERGAN PLC | Comptroller/Controller/Auditor | 01/01/2020 |
Merck Sharp & Dohme Corp.
 Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. | Comptroller/Controller/Auditor | 01/01/2015 |
Formation de Kathryn DiMarco
| Lehigh University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ORGANON & CO. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. | Health Technology |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
